Artizan’s President and Chief Executive Officer, Dr. Martell, is a seasoned biopharmaceutical executive with high-impact, results-oriented breadth and depth in clinical development, medical affairs and business development across a range of therapeutic areas from first-in-human through approval and commercialization. She brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogivri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell has held leadership and C-suite executive roles at companies including Kura Oncology, where she led the Menin Inhibitor Program, and at Juniper Pharmaceuticals, where she led the development program for a Bob Langer-created drug/device technology that was out-licensed for $131M. She started her pharmaceutical career at Pfizer, where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and, ultimately, Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award, where she led a therapeutic cocaine vaccine trial and was a Robert Wood Johnson Clinical Scholar. Dr. Martell was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. She holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University and an M.D. from The Chicago Medical School. Dr. Martell is board certified in Internal and Addiction Medicine.
Toggle navigation